Trial Profile

A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokintetics, and Pharmacodynamics of REC-4881 in Patients with Familial Adenomatous Polyposis (FAP)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Feb 2026 According to a Recursion Pharmaceuticals media release, the company to initiate FDA engagement in 1H26 to align on a potential registration pathway for REC-4881, alongside ongoing dosing optimization and expansion of TUPELO to include patients aged 18+ to support a broader development strategy. Additional Phase 1b/2 clinical data expected in 1H27.
08 Dec 2025 Results presented in the Recursion Pharmaceuticals Media Release.
05 Nov 2025 According to a Recursion Pharmaceuticals media release, Additional data in FAP from the Phase 2TUPELO study expected in December 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com